Edoxaban, a highly selective, once-daily, direct, reversible inhibitor of Factor Xa was approved for stroke prevention in patients with AF in Europe in 2015, as well as for the treatment and secondary prevention of venous thromboembolism (VTE) in adults. The gene discussed is F10; the disease is atrial fibrillation.